Osman Kibar (Samumed, now Biosplice)

Os­man Kibar lays down his hand at Sa­mumed, step­ping away from CEO role as his once-her­ald­ed an­ti-ag­ing biotech re­brands

Sa­mumed made quite the en­trance back in 2016, when it launched with some an­ti-ag­ing pro­grams and a whop­ping $12 bil­lion val­u­a­tion. That lev­el of fan­fare was nowhere to be found on Thurs­day, when the com­pa­ny added an­oth­er $120 mil­lion to its cof­fers and qui­et­ly changed its name to Bios­plice Ther­a­peu­tics.

Why the sud­den re­brand?

“We did that for ob­vi­ous rea­sons,” CFO and CBO Erich Hors­ley told End­points News. “The name Bios­plice echoes our sci­ence much more than Sa­mumed does.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.